OncoMark to Present Key Study on OncoMasTR Test for Early Stage Breast Cancer at ASCO 2019 in Chicago
Presentation will highlight superior clinical performance of the OncoMasTR test in Irish patients enrolled in the TAILORx Trial
OncoMark Ltd (www.oncomark.com) will be presenting results from a study on the clinical performance of OncoMasTR, the company’s prognostic test for early stage breast cancer at the 2019 American Society for Clinical Oncology (ASCO) annual meeting. This meeting will be held in Chicago from 31 May -4 June.
Speaking in advance of the annual meeting Des O’Leary, CEO of OncoMark, said, "We are excited that further analysis of the OncoMasTR test in the Irish patients enrolled in the TAILORx Trial will be presented at this year’s ASCO meeting. The presentation will demonstrate how the OncoMasTR Test offers a better solution compared to conventional breast cancer prognostic tools and molecular tests in accurately identifying women who can safely forego chemotherapy in the treatment of breast cancer.”
Details of the poster presentation on OncoMark’s OncoMasTR test at the 2019 ASCO meeting are as follows:
Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland
by Darran O’Connor, Royal College of Surgeons in Ireland, Dublin, Ireland.
Session - Breast Cancer: Local/Regional/Adjuvant, Abstract Number #535: Sunday 2 June, 8:00m – 11:00am.